1. Title of Derivative Security (Instr. 4) |
2. Date Exercisable and Expiration Date (Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) |
4. Conversion or Exercise Price of Derivative Security |
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) |
6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
Stock Option (Right to Buy)
|
Â
(2)
|
11/11/2026 |
Common Stock
|
37,500
|
$
4.9
|
D
|
Â
|
Stock Option (Right to Buy)
|
Â
(3)
|
03/15/2027 |
Common Stock
|
5,000
|
$
2.37
|
D
|
Â
|
Stock Option (Right to Buy)
|
Â
(4)
|
05/11/2027 |
Common Stock
|
25,000
|
$
1.56
|
D
|
Â
|
* |
If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** |
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) |
Consists of 2,500 Restricted Stock Units granted pursuant to the Aralez Pharmaceuticals Inc. 2016 Amended and Restated Long-Term Incentive Plan, which vest in substantially equal annual installments over the three years immediately following the date of grant (March 15, 2017), subject to continued employment or service to the Company. |
(2) |
The option vests in substantially equal monthly installments over four years from date of grant (November 11, 2016), subject to continued employment or service to the Company. |
(3) |
The option vests in substantially equal monthly installments over four years from date of grant (March 15, 2017), subject to continued employment or service to the Company. |
(4) |
The option vests as to 25% of the shares on May 11, 2018, and the remainder vests in substantially equal monthly installments over the 36 months immediately following such date, subject to continued employment or service to the Company. |